Skip to content
Alligator Bioscience

Alligator Bioscience

En till WordPress-webbplats

  • Swedish
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • ADC-1013
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Technology platform
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors and collaborators
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Subscribe
  • Contact
  • Swedish
Start > Investors > Analysts
  • Investors
    • Share and shareholders
    • Analysts
    • IPO
    • Financial reports
    • Calendar
    • Presentations

Analysts

The Alligator Bioscience share is covered by the following analysts:

Carnegie
Erik Hultgård/Jacob Lademann – Tel:+46 8 676 88 00

DNB
Patrik Ling – Tel: +46 8 473 48 43

Redeye Securities
Klas Palin – Tel:+46 8 545 01 344

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Investors
  • News
  • Contact

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 286 4280

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2017 - Alligator Bioscience AB